パレクセル インサイトへ戻る

Follow our patients on their pathway to CAR-T trial participation

Patient Pathways

Patient C

  • Does have a referral from a HCP
  • Does live near a CAR-T trial site
  • Is financially able to travel, hire caregivers, and/or be absent from work
  • Can rely on a dedicate caregiver
  • Does not meet the inclusion/exclusion criteria within the specified timeframe
Patient Outcome

Patient C is excluded from trial enrollment as there are strict inclusion and exclusion criteria.

After appropriate HCP referral, patients can often face hurdles in meeting clinical criteria and/or running out of time while healthy enough to enroll.

What we learned about the journey to CAR-T therapy

1. Patients' diagnostic and treatment journeys are unique:

Diagnostic and treatment journeys leading to consideration of a CAR-T therapy vary significantly from person-to-person.

The FDA approves these trials...and the doctor cannot deviate from the protocol. An example I'll give is the bone marrow biopsy. In the three times she had Lymphoma, she never had any positive bone marrow, and because of the protocol she had to get four different bone marrow biopsies...it got to be too much

The caregiver's perspective

2. Socioeconomic factors and complex inclusion/exclusion criteria prevent patient participation:

Complex inclusion/exclusion criteria and a lack of access to resources can preclude potential study participants, especially from underrepresented populations.

There is socioeconomic disparity between those that can go through CAR-T and those that financially or logistically cannot.

The HCP's perspective

Our Methodology

Literature review of CAR-T and related clinical trial challenges, internal Parexel presentations

4 Qualitative HCP in-depth interviews
Hematology/Oncology, Clinical Trial Coordinator, Parexel medical Directors and Parexel Nurse Advisor

104 Quantitative surveys 
patients familiar with or who have received CAR-T therapy for their hematological malignancy 

5 Qualitative patient and caregiver in-depth interviews 
patients who have received CAR-T in a clinical trial 

今、何が可能なのかを知りましょう

弊社の専門家による斬新な思考と実行可能なインサイトで、最新情報を入手してください。

お問い合わせ

パレクセルの細胞・遺伝子治療研究について

パレクセルでは、患者さんの治療経過に対する深い理解を基盤とした革新的な試験デザインを提供しています。弊社の細胞・遺伝子治療センター オブ エクセレンスは、開発ライフサイクル全体を通じてベストプラクティスを収集し、頻繁に変更される規制上のハードルを乗り越え、患者さんへの治療を加速させるために、お客様を支援します。パレクセルはスポンサーが規制上の経路を管理し、コンプライアンスリスクを軽減することで、概念実証 (PoC)から販売承認までのプロセスをより迅速かつ効率的に進められるようサポートします。

パレクセルと協力して、細胞・遺伝子治療の開発を加速し、市場での成功の可能性を最大限に高めましょう。

詳しくはこちら